GALT

Galectin Therapeutics Inc. Press Releases

$6.6
*  
0.90
15.79%
Get GALT Alerts
*Delayed - data as of Jul. 30, 2014  -  Find a broker to begin trading GALT now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    GALT After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Ryan & Maniskas, LLP Announces Investigation of Galectin Therapeutics, Inc.
7/30/2014 1:00:00 PM - PR Newswire

Galectin Therapeutics Issues Statement on GR-MD-02 Development Program
7/30/2014 9:07:00 AM - GlobeNewswire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics, Inc. - GALT
7/29/2014 5:32:00 PM - PR Newswire

GALECTIN SHAREHOLDERS NOTICE: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Galectin Therapeutics Inc.
7/29/2014 2:58:00 PM - Business Wire

Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis
7/25/2014 8:00:00 AM - GlobeNewswire

Galectin Therapeutics Announces First Patient Dosed in Cohort 1 of Phase 1B Clinical Trial of GR-MD-02 in Combination with Ipilimumab in Metastatic Melanoma
7/22/2014 8:30:00 AM - GlobeNewswire

Galectin Therapeutics Added to Russell 2000 Index
7/9/2014 8:30:00 AM - GlobeNewswire

Galectin Therapeutics Announces That Oral Treatment With Galectin-3 Inhibitor GR-MD-02 is Efficacious in Preclinical Model of Fatty Liver Disease With Fibrosis
6/23/2014 8:00:00 AM - GlobeNewswire

Galectin Therapeutics to Present at Jefferies 2014 Global Healthcare Conference
5/29/2014 8:00:00 AM - GlobeNewswire

Galectin Therapeutics Receives U.S. Patent for GR-MD-02 in Diabetic Nephropathy, a Progressive Kidney Disease
5/28/2014 8:00:00 AM - GlobeNewswire

Galectin Therapeutics Reports First Quarter 2014 Financial Results
5/13/2014 5:00:00 PM - GlobeNewswire

Galectin Therapeutics to Hold Conference Call to Provide Corporate Update Following Company's Annual Meeting of Shareholders
5/8/2014 8:00:00 AM - GlobeNewswire